HOME ·

HAIXI PHARMA

HAIXI PHARMA (02637.HK): HX9428 Phase I and Phase II nAMD data show continued BCVA improvement
Tags：
HAIXI PHARMA02637.HKR&D Progress
2026-09-16
HAIXI PHARMA (02637.HK): Oral Retinal Disease Drug HX9428 Files Phase IIa IND for Diabetic Macular Edema; Phase I Data in nAMD Disclosed
Tags：
HAIXI PHARMA02637.HKR&D Progress
2026-09-02
Going Global Weekly Report: Pharma Overseas Expansion Blossoms Across Fronts, A-Share Companies Accelerate Hong Kong Listings - 20260821
Tags：
Going Global Weekly ReportHENLIUSSINOPEC SSCINGENICHAIXI PHARMA
2026-08-21
HAIXI PHARMA (02637.HK): HX9428 for Neovascular Age-Related Macular Degeneration Granted Fast Track Designation by US FDA
Tags：
HAIXI PHARMA02637.HKResearch Progress
2026-08-17
HAIXI PHARMA(02637.HK): HX9428 for nAMD Cleared by US‑FDA for Phase II Trial; Positive‑Control Phase II Study Initiated in China
Tags：
HAIXI PHARMA02637.HKClinical Trial
2026-08-04
HAIXI PHARMA (02637.HK): IND Application of HXP089 for Glioblastoma Approved by NMPA
Tags：
HAIXI PHARMA02637.HKIND Approval
2026-07-14
HAIXI PHARMA(02637.HK): Phase III Clinical Trial of C019199 Tablets for Osteosarcoma Initiated
Tags：
HAIXI PHARMA02637.HKClinical Trial
2026-07-09
HAIXI PHARMA(02637.HK) closed 11.55% higher
Tags：
HAIXI PHARMA02637.HK
2026-04-24